Earnings History Data for Enliven Therapeutics, Inc. (ELVN) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Enliven Therapeutics, Inc.
Enliven Therapeutics Inc. is a clinical-stage precision oncology company focused on the discovery and development of small molecule kinase inhibitors. The Company's lead product candidate includes ELVN-001 and ELVN-002. Enliven Therapeutics Inc., formerly known as Imara Inc., is based in Boulder, CO.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13-11-2024 | AH | ELVN | Enliven Therapeutics, Inc. | 1,305 | -0.48 | -0.52 | 0.00 | Enliven Therapeutics GAAP EPS of -$0.48 beats by $0.02 [11/13/2024 6:12 PM] |
24.85 | -0.95 (-3.68%) |
25.80 | 0.0 (0.00%) |
9.80 - 30.03 | 151,599 | 310,000 | 4,186 | ||
| 13-08-2024 | PM | ELVN | Enliven Therapeutics, Inc. | 1,003 | -0.41 | -0.58 | 0.00 | Enliven Therapeutics GAAP EPS of -$0.41 [8/14/2024 9:15 AM] |
21.78 | 0.26 (1.21%) |
21.52 | 0.0 (0.00%) |
9.80 - 27.67 | 69,648 | 240,000 | 7,029 | ||
| 14-05-2024 | PM | ELVN | Enliven Therapeutics, Inc. | 1,101 | -0.54 | -0.58 | 0.00 | Enliven Therapeutics GAAP EPS of -$0.54 beats by $0.02 [5/15/2024 6:24 AM] |
23.97 | 0.10 (0.42%) |
23.87 | 0.0 (0.00%) |
9.80 - 26.00 | 359,106 | 330,000 | 47,133 | ||
| 14-03-2024 | AH | ELVN | Enliven Therapeutics, Inc. | 525.00 | -0.47 | -0.56 | 0.00 | Enliven Therapeutics GAAP EPS of -$0.47 [3/14/2024 5:24 PM] |
12.04 | 0.50 (4.33%) |
11.54 | 0.0 (0.00%) |
9.80 - 24.22 | 573,986 | 70,000 | 4,833 | ||
| 09-11-2023 | AH | ELVN | Enliven Therapeutics, Inc. | 515.00 | -0.51 | -0.49 | 0.00 | Enliven Therapeutics GAAP EPS of -$0.51 [11/9/2023 5:42 PM] |
11.42 | -0.13 (-1.13%) |
11.55 | 0.0 (0.00%) |
10.89 - 25.34 | 71,505 | 50,000 | 1,704 | ||
| 11-05-2023 | AH | 4:40 PM ET (May 11) |
ELVN | Enliven Therapeutics, Inc. | 126.00 | -0.80 | -0.67 | 0.00 | Enliven Therapeutics GAAP EPS of -$0.80 misses by $0.28 [5/11/2023 5:01 PM] |
19.41 | 0.31 (1.62%) |
19.10 | 0.0 (0.00%) |
4.04 - 25.34 | 85,252 | 80,000 | 131 | |